EUVIMEDSkopri EUVIMED
EUVIMED · CrossrefJournal

European Journal of Pain

ISSN 1090-3801 · Wiley

Latest articles

  1. The Impact of Outcome Measures for Responder Analyses in Placebo‐Controlled Trials of Pharmacological Treatments for Neuropathic Pain

    Nanna Brix Finnerup, Sandra Sif Gylfadottir, Xavier Moisset, Andrea Truini, Ralf Baron, David L. Bennett, Margarita Calvo, Daniel Ciampi de Andrade, Patrick M. Dougherty, Elena K. Enax‐Krumova, Michael C. Ferraro, Ian Gilron, Aki Hietaharju, David Hohenschurz‐Schmidt, Koichi Hosomi, Harriet I. Kemp, Ewan McNicol, Jules Phalip, Theodore J. Price, Srinivasa N. Raja, Cristina Ramirez Piriz, Andrew S. C. Rice, Blair H. Smith, Nina Taule‐Lim, Jan Vollert, Jan D. Wandrey, Mohammad D. Zunaid, Nadine Attal, Simon Haroutounian

    Published: 2026-11DOI: 10.1002/ejp.70448

  2. Prescription Trends and Clinical Decision‐Making in Neuropathic Pain Pharmacological Treatment: Results From a Cross‐Sectional Survey by the Spanish Pain Society

    Miguel Á. Huerta, Mónica Mayo‐Moldes, Miguel M. Garcia, Beliu García‐Parra, Mercè Matute, Yolanda López‐Tofiño, Nancy Paniagua, Mar Hernández‐Secorún, Dolors Soler, Marcos Salmerón, Julian Taylor, Enrique Verdú, José A. Valencia, Silvia Pico, Clara Díaz‐Alejo, Masahito Katsuki, Ancor Serrano‐Afonso, M. Carmen Ruiz‐Cantero

    Published: 2026-03DOI: 10.1002/ejp.70246

Volumes

2026 · 2222025 · 2722024 · 1602023 · 1232022 · 1952021 · 1912020 · 1832019 · 1872018 · 1812017 · 1842016 · 1862015 · 1942014 · 1712013 · 1752012 · 1722011 · 1762010 · 1742009 · 1,1902008 · 1272007 · 5842006 · 1,0862005 · 882004 · 792003 · 802002 · 692001 · 832000 · 621999 · 761998 · 521997 · 58

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.